Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.65 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1188233 | 1.00 | S1PR5 (0.65) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL1188230 | 1.00 | S1PR5 (0.65) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL6231248 | 1.00 | S1PR5 (0.65) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL29955331 | 0.92 | S1PR5 (0.56) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL1891761 | 0.90 | S1PR5 (0.58) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL4522412 | 0.90 | FUCA1 (0.67) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL23297889 | 0.88 | S1PR5 (0.56) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL1893897 | 0.88 | S1PR5 (0.56) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL22435919 | 0.88 | S1PR5 (0.56) | S1PR5S1PR1FUCA1RORCALDH1A1 | |
| SCHEMBL874162 | 0.88 | S1PR5 (0.56) | S1PR5S1PR1FUCA1RORCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | S1PR5 634/4885S1PR1 418/4885FUCA1 2832/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | S1PR5 595/4885S1PR1 393/4885FUCA1 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.